Prolium Bioscience Announces First Patient Dosed in its Multinational, Phase 1/2 Study of PRO-203 in Systemic Sclerosis, and Last Patient, Last Visit in an Investigator-Led ...

Phase 1/2 SSc study is expected to enroll patients at over 20 participating clinical sites in at least five countries Recently completed Phase 1 Single Ascending Dose study of PRO-203 in healthy ...

Prolium Bioscience Announces First Patient Dosed in its Multinational, Phase 1/2 Study of PRO-203 in Systemic Sclerosis, and Last Patient, Last Visit in an Investigator-Led ...

Phase 1/2 SSc study is expected to enroll patients at over 20 participating clinical sites in at least five countriesRecently completed Phase 1 ...
Business Wire

IFF Launches SENSORA™, an Innovative Pro-Fragrance Technology Platform

IFF (NYSE: IFF) — a global leader in flavors, fragrances, food ingredients and health and biosciences — today announced the ...

People Who Like This 1 Food Have Lower Risk of Diabetes and Hypertension, Doctors Say

Experts break it down.
Condé Nast Traveler

Biohacking Has Taken Over the Wellness Space—So What's a Gimmick, and What Actually Works?

When it comes to traveling for medi spas and biohacking retreats, only some clinics are actually worth their salt. Here's ...

Markets news, June 30, 2026: Major indexes advance on final day of strongest quarter since 2020; oil prices slip

Stocks ended their best quarter since 2020 on a high note. The tech-focused Nasdaq Composite, benchmark S&P 500, and ...

Interpace Biosciences Announces First Quarter 2026 Financial and Business Results

Detailed price information for Interpace Biosciences Inc (IDXG) from The Globe and Mail including charting and trades.
Engineering News-Record

Data Centers and Housing Drive Growth in Des Moines

The city is seeing development on many fronts, including tech, manufacturing and the burgeoning downtown district.